Dr. Nadia Isabel Abelhad, MD

Dr. Abelhad practices at Holy Cross Health in Fort Lauderdale, Florida, part of Trinity Health.

Dr. Abelhad's NPI, 1619400801, was assigned on April 5, 2017. Dr. Abelhad graduated from McGovern Medical School in 2017. Dr. Abelhad holds California license A183741.

Dr. Abelhad's primary practice is Holy Cross Health, at 4725 N Federal Hwy, Fort Lauderdale, FL 33308 in Broward County. The practice phone is (954) 771-8000.

Dr. Abelhad's primary practice is Holy Cross Health in Fort Lauderdale, Florida, part of Trinity Health. Dr. Abelhad is also affiliated with Sharp Chula Vista Medical Center. The medical group on file is Holy Cross Medical Group. Dmand AI also links Dr. Abelhad to 4 more group practices and clinics and 4 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Abelhad practices, 6 sites in all. Vendor and product names are available with a free account.

Cardiovascular disease is Dr. Abelhad's primary specialty in the NPI Registry, under taxonomy code 207RC0000X. Dr. Abelhad is board certified in cardiovascular disease by the American Board of Internal Medicine. Dmand AI has Dr. Abelhad's licenses on file in 3 states: California, Louisiana and Texas.

Dmand AI lists atrial fibrillation and flutter, chronic hypertension, coronary artery disease, heart valve disorders, high cholesterol and tobacco use among the conditions Dr. Abelhad treats.

CMS data shows 1,088 Medicare services from Dr. Abelhad across 14 procedure codes in 2024, for 486 Medicare patients. Medicare paid $116,928 for them.

CMS counts 486 Medicare patients who saw Dr. Abelhad in 2024. The largest group is 65 to 74, with 219 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 66% are also on Medicaid. Their average risk score is 1.85, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Abelhad's median patient age at 63, with 53% women.

In 2024, Dr. Abelhad wrote 950 Medicare Part D claims for 245 patients. 79% of them were for generic drugs. CMS names the drug for 817 of them, across 23 drugs with 11 or more claims each, at $153,716 in total drug cost. In 2023, CMS named 388 claims across 16 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Abelhad for performance year 2024, reported as part of a group. Dr. Abelhad accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Abelhad as offering telehealth.

Dmand AI links 12 papers to Dr. Abelhad, published from 2018 to 2024. 2021 was the busiest year, with 3. The most frequent topics are Myocardial Infarction. Dr. Abelhad has published most often in Thromb J. Dr. Abelhad's most frequent co-authors are Naveen Garg, MD, Cristhiam Mauricio Rojas-Hernandez, MD and William Austin West, MD.

CMS Open Payments shows 234 general payments to Dr. Abelhad from 34 drug and device companies from 2019 to 2025. Food and beverage make up the largest share, 71% of the total. Biotronik Inc. paid the most, $4,685.

Dr. Abelhad graduated from McGovern Medical School in 2017.

Dr. Abelhad is in network with 17 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Elevance. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.